Day 2 │Wednesday 1 February

KEYNOTE LECTURE

Chair: Taija Mäkinen

8.30 – 9.10

In search of novel ways to modulate the PI3K pathway for therapeutic benefit

Bart Vanhaesebroeck │ UCL Cancer Institute, London, UK

9.10 – 9.15

Patient story

SESSION VENOUS/LYMPHATIC MALFORMATIONS AND PI3K SIGNALING

Chairs: Mariona Graupera and Emmanuel Seront

9.15 – 9.35

Metabolic decisions in vascular growth and differentiation

Michael Potente │VA Cure - Berlin Institute of Health at Charité (BIH), Berlin, Germany

9.35 – 9.50

Contribution of mechanical forces from blood flow in neurovascular arteriovenous malformations

Nicolas Baeyens │ ULB, Belgium

9.50 – 10.05

Loss of myogenic activity in smooth muscle cells as driver of arterio-venous and lymphatic malformations

Michael Orlich │ Uppsala University, Sweden

10.05 – 10.20

Pathogenic mechanisms of lymphatic malformations

Taija Mäkinen │ VA Cure – Uppsala University, Sweden

10.20 – 10.35

Clonal origin of Pik3ca-driven lymphatic malformations

Hans Schoofs │ VA Cure – Uppsala University, Sweden

10.35 – 11.05

Coffee break

11.05 – 11.20

Proteasome Inhibitors and Proteostasis Defects in Venous and Lymphatic Malformations Downstream of PI3K/mTOR Hyperactivation

Carrie Shawber │ Columbia University Medical Center, USA

11.20 – 11.50

Targeted therapies in PIK3CA-related vascular anomalies

Guillaume Canaud │ Hôpital Necker Enfants Malades and Université Paris Cité, Paris, France

11.50 – 12.05

ART-001, an orally-available PI3Kα inhibitor for slow-flow vascular malformations: a phase 2 randomized, double-blind trial

Akihiro Fujino │ National Center for Child Health and Development, Japan

POSTER TEASERS

Chairs: Mariona Graupera and Emmanuel Seront

12.05 – 12.10

New capillary lymphatic endothelial cell subtype as a driver of lymphatic malformation pathology

Milena Petkova │ Uppsala University, Sweden 

12.10 – 12.15

Immunothrombosis and vascular heterogeneity in cerebral cavernous malformation

Maria Globisch │ Uppsala University, Sweden

12.15 – 12.20

RASA1 and BRAF variants in a patient with capillary malformation-arteriovenous malformation 1 (CM-AVM1) and primary lymphedema, treated with a MEK inhibitor.

Isabelle Quere │ CHU - University of Montpellier

12.20 – 13.00

Lunch

POSTER SESSION

13.00 – 14.30

Poster session 1 (even numbers + teasers from Tuesday and Wednesday)

KEYNOTE LECTURE

Chair: Salim Seyfried

14.30 – 15.10

Deciphering the complex genomic architecture of moyamoya, an avenue towards the pathophysiology of this mysterious cerebral angiopathy

Elisabeth Tournier-Lasserve │ Saint Louis Hospital, Paris - Paris Cité University

SESSION CEREBRAL CAVERNOUS MALFORMATIONS & MAP3K3 SIGNALING

Chairs: Joyce Bischoff and Bojana Lazovic

15.10 – 15.40

“Going under the skin” – intravital imaging of disturbed vascular flow and blood clot formation in CCM

Konstantin Gängel │ Uppsala University, Sweden

15.40 – 15.55

CCM2 loss induces a mechano-dependent endothelial mosaicism

Apeksha Shapeti │ KU Leuven, Belgium

15.55 – 16.15

Coffee break

16.15 – 16.30

Hypoxia-induced immunothrombosis and exacerbation of cerebral cavernous malformation disease

Miguel A. Lopez-Ramirez │ University of California, San Diego, USA

16.30 – 16.45

Targeting NETosis in cerebral cavernous malformation

Favour Onyeogaziri │ Uppsala University, Sweden

16.45 – 17.05

Studying the role of biomechanics in vascular disease models in zebrafish

Salim Seyfried │ VA Cure – Potsdam University, Germany

17.05 – 17.20

The Polycomb Repressive Complex 1 protein Cbx7a activates pathogenic Klf2 targets in a Zebrafish model of Cerebral Cavernous Malformations

Cuong Pham │ VA Cure – Potsdam University, Germany

17.20 – 17.50

How can preclinical research help CCM patients: focus on two cases, propranolol and atorvastatin

Roberto Latini │ Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy

Dinner on your own